Emerging Targeted Therapies in Relapsed/Refractory Acute Lymphoblastic Leukemia

This webcast on relapsed/refractory acute lymphoblastic leukemia (R/R ALL) is based on a roundtable discussion by three experts, who provide an overview of challenges in the treatment of R/R ALL and summarize and discuss the latest data presented during the European Hematology Association (EHA) Annual Congress 2017, held on June 22–25 in Madrid, Spain. Progressing clinical trial outcomes of targeted therapies for R/R ALL, such as the anti-CD22 immunoconjugate inotuzumab ozogamicin, the anti-CD19 bi-specific T-cell engager (BiTE) blinatumomab, and CAR-T cell therapy will be examined. The experts will address the question of how novel treatment options could be included in individualized treatment plans when approved, to optimize treatment selection and outcomes for patients with R/R ALL.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with R/R ALL.

LEARNING OUTCOMES STATEMENT

At the conclusion of this activity:

KNOWLEDGE: Participants will self-report knowledge gained based on novel therapies that may be used to optimize outcomes for patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

COMPETENCE/SKILL: Participants will self-report intent to change partice by applying knowledge gained based on novel therapies that may be included to optimize outcomes for patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to:

  1. Describe: the various surface antigens expressed in B-cell acute lymphoblastic leukemia (B-ALL); the rationale for targeting antigens as a treatment strategy; and the mechanism of action (MoA) of targeted therapies and emerging targeted therapies such as the anti-CD22 immunoconjugate inotuzumab ozogamicin and the anti-CD19 BiTE blinatumomab.
  2. State the efficacy and safety of novel therapies including CAR-T cell therapy, based on progressing clinical trial outcomes as presented at the EHA Annual Congress 2017.
  3. Determine where these novel treatments could fit in data-driven treatment plans, and how to select eligible R/R ALL patients in daily clinical practice (when approved).

FACULTY

David Marks, MD
Professor and Director of BMT Unit
Bristol Haematology and
Oncology Centre
Bristol, UK

Hagop M. Kantarjian, MD
Department Chair, Professor
Leukemia Department
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, TX, USA

Elias Jabbour, MD
Associate Professor
Leukemia Department
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, TX, USA

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education (EOCME) and Elsevier that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their life partner have with commercial interests related to the content of this interprofessional educational activity:

FacultyRelationship Identified With:

David Marks, MB, BS, PhD, FRACP, FRCPath

Consultant/Advisor: Pfizer Inc., Amgen Inc.

Speakers Bureau: Pfizer Inc., Amgen Inc.

Hagop M. Kantarjian, MD

Consultant/Advisor: Actinium Pharmaceuticals Inc.

Grant/Research Support: Amgen Inc., ARIAD Pharmaceuticals, Inc., Astex Pharmaceuticals

Speakers Bureau: Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Amgen Inc., ARIAD Pharmaceuticals, Inc., ImmunoGen, Inc., Astex Therapeutics, AbbVie, Inc.

Elias Jabbour, MD

Consultant/Advisor: Amgen Inc., Pfizer Inc., Takeda Pharmaceuticals U.S.A., Inc.

Grant/Research Support: Amgen Inc., Pfizer Inc., Takeda Pharmaceuticals U.S.A., Inc.

Non-faculty reported the following financial relationships or relationships to products or devices they or their life partner have with commercial interests related to the content of this CME activity:

Nabil Dorkhom, Elena Knoche, Cordelia Nagle, Marijke Verhaaf, Marilu Kelly, MSN, RN, CNE, Bernard M. Abrams, MD, Sandy Breslow and Alison Kemp hereby state that neither they nor their life partners have had any financial relationships with products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Amgen.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education (EOCME), Elsevier and Excerpta Medica (EM).

CME Credit (Physicians)

The Elsevier Office of Continuing Medical Education (EOCME) is accredited by the ACCME to provide continuing medical education for physicians.

The EOCME designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu. Additional information on the process of converting AMA PRA Category 1 Credit™ to ECMECs® can be found at: www.eaccme.eu.

CNE Credit (Nurses)

This continuing nursing education activity, provided by Elsevier, awards 1.0 contact hours for nurses. Elsevier is accredited with distinction as a provider of continuing education by the American Nurses Credentialing Center's Commission on Accreditation. Elsevier is provider approved by the Flordida Board of Nursing, Provider #50-4681, and the California Board of Registered Nursing, Provider #CEP 3257.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the EOCME, Elsevier and EM.

CME/CNE INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.

For all CNE inquiries or special needs, please contact p.harvey@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). The EOCME, Elsevier, Excerpta Medica, and Amgen do not recommend the use of any agent outside the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Nursing Contact Hours
  • 1.00 Non-physician
Course opens: 
10/15/2017
Course expires: 
10/14/2018
Rating: 
0

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Nursing Contact Hours
  • 1.00 Non-physician

Accreditation Period

Course opens: 
10/15/2017
Course expires: 
10/14/2018
Please login or register to take this course.